PCSK9 and myeloid sarcoma: PCSK9, previously identified in other proteomic studies as being less abundant in the serum of MS patients compared to individuals with non-inflammatory neurological diseases (18) showed a lower AR in PPMS compared to RRMS during the exploratory phase; however, this difference was not significant in the validation phase.